Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving out...
For reduction of mortality in patients with severe sepsis.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.